Quarterly Results - |
|||
|
Fiscal Q2 2020 |
Change vs. Fiscal Q2 2019 |
Change vs. Fiscal Q1 2020 |
Net Revenue |
|
up 30.1% |
up 4.4% |
Gross Profit |
|
up 24.6% |
down 1.6% |
Gross Margin |
46.0% |
down 190 bps |
down 280 bps |
Income from Operations |
|
up 544% |
down 17.2% |
Operating Margin |
7.3% |
up 950 bps |
down 200 bps |
Net Income |
|
up 430.6% |
down 11.9% |
|
7.9% |
up 1100 bps |
down 150 bps |
EPS – Diluted(a) |
|
up 480% |
down 9.5% |
(a) |
GAAP diluted net earnings per share reflects any dilutive effect of outstanding restricted stock units and stock options, but that effect is excluded when calculating GAAP diluted net (loss) per share because it would be anti-dilutive. For the three months ended |
Quarterly Results - Non-GAAP |
|||
|
Fiscal Q2 2020 |
Change vs. Fiscal Q2 2019 |
Change vs. Fiscal Q1 2020 |
Income from Operations |
|
up 1175% |
down 17.3% |
Operating Margin |
8.6% |
up 970 bps |
down 220 bps |
Net Income |
|
up 6750% |
down 12.7% |
|
9.1% |
up 890 bps |
down 180 bps |
EPS - Diluted |
|
NA |
down 8.3% |
A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial tables included in this release. See also “Use of non-GAAP Financial Results” section.
Dr.
The Company's manufacturing facility in
Second Quarter Fiscal 2020 Financial Highlights
- Net revenue of
$150.7 million . - Gross margin of 46.0%.
- Net income of
$11.9 million or$0.19 per share; non-GAAP net income of$13.7 million or$0.22 per share. - Cash, cash equivalents, and short-term investments, net of bank overdraft facility were
$524.7 million as ofMarch 28, 2020 .
Third Quarter Fiscal 2020 Outlook
The Company currently expects net revenue in the third fiscal quarter of 2020 ending
Looking forward, Dr.
Earnings Conference Call Details
A conference call to discuss these results will be held tomorrow,
A replay will be available from approximately one hour after the completion of the call through
Use of Non-GAAP Financial Results
In addition to
Management uses both
About Kulicke & Soffa
Leveraging decades of development proficiency and extensive process technology expertise, Kulicke & Soffa’s expanding portfolio provides equipment solutions, aftermarket products and services supporting a comprehensive set of interconnect technologies including wire bonding, advanced packaging, lithography, and electronics assembly. Dedicated to empowering technological discovery, always, K&S collaborates with customers and technology partners to push the boundaries of possibility, enabling a smarter future (www.kns.com).
Caution Concerning Results and Forward-Looking Statements
In addition to historical statements, this press release contains statements relating to future events and our future results. These statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our judgments and future expectations concerning our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to the factors listed or discussed in our 2019 Annual Report on Form 10-K, our Current Report on Form 8-k filed
|
|||||||||||||||
|
Three months ended |
|
Six months ended |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Net revenue |
$ |
150,741 |
|
|
$ |
115,908 |
|
|
$ |
295,038 |
|
|
$ |
273,116 |
|
Cost of sales |
81,438 |
|
|
60,335 |
|
|
155,371 |
|
|
142,744 |
|
||||
Gross profit |
69,303 |
|
|
55,573 |
|
|
139,667 |
|
|
130,372 |
|
||||
|
|
|
|
|
|
|
|
||||||||
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Selling, general and administrative |
27,331 |
|
|
27,235 |
|
|
53,755 |
|
|
55,768 |
|
||||
Research and development |
29,067 |
|
|
29,577 |
|
|
57,359 |
|
|
59,380 |
|
||||
Amortization of intangible assets |
1,820 |
|
|
1,869 |
|
|
3,637 |
|
|
3,746 |
|
||||
Restructuring |
9 |
|
|
(643 |
) |
|
426 |
|
|
(612 |
) |
||||
Total operating expenses |
58,227 |
|
|
58,038 |
|
|
115,177 |
|
|
118,282 |
|
||||
Income/(loss) from operations |
11,076 |
|
|
(2,465 |
) |
|
24,490 |
|
|
12,090 |
|
||||
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest income |
2,675 |
|
|
3,865 |
|
|
5,514 |
|
|
7,691 |
|
||||
Interest expense |
(661 |
) |
|
(254 |
) |
|
(1,244 |
) |
|
(505 |
) |
||||
Income before income taxes |
13,090 |
|
|
1,146 |
|
|
28,760 |
|
|
19,276 |
|
||||
Income tax expense |
1,162 |
|
|
4,672 |
|
|
3,295 |
|
|
15,242 |
|
||||
Share of results of equity-method investee, net of tax |
40 |
|
|
29 |
|
|
100 |
|
|
72 |
|
||||
Net income /(loss) |
$ |
11,888 |
|
|
$ |
(3,555 |
) |
|
$ |
25,365 |
|
|
$ |
3,962 |
|
|
|
|
|
|
|
|
|
||||||||
Net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.19 |
|
|
$ |
(0.05 |
) |
|
$ |
0.40 |
|
|
$ |
0.06 |
|
Diluted |
$ |
0.19 |
|
|
$ |
(0.05 |
) |
|
$ |
0.39 |
|
|
$ |
0.06 |
|
|
|
|
|
|
|
|
|
||||||||
Cash dividends declared per share |
$ |
0.12 |
|
|
$ |
0.12 |
|
|
$ |
0.24 |
|
|
$ |
0.24 |
|
|
|
|
|
|
|
|
|
||||||||
Weighted average shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
63,679 |
|
|
65,930 |
|
|
63,675 |
|
|
66,530 |
|
||||
Diluted |
64,219 |
|
|
65,930 |
|
|
64,266 |
|
|
67,344 |
|
|
Three months ended |
|
Six months ended |
||||||||||||
Supplemental financial data: |
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
$ |
4,769 |
|
|
$ |
5,237 |
|
|
$ |
9,528 |
|
|
$ |
10,006 |
|
Capital expenditures |
2,775 |
|
|
2,234 |
|
|
5,099 |
|
|
7,176 |
|
||||
Equity-based compensation expense: |
|
|
|
|
|
|
|
||||||||
Cost of sales |
183 |
|
|
160 |
|
|
415 |
|
|
310 |
|
||||
Selling, general and administrative |
2,695 |
|
|
2,330 |
|
|
5,430 |
|
|
5,255 |
|
||||
Research and development |
844 |
|
|
811 |
|
|
1,486 |
|
|
1,609 |
|
||||
Total equity-based compensation expense |
$ |
3,722 |
|
|
$ |
3,301 |
|
|
$ |
7,331 |
|
|
$ |
7,174 |
|
|
As of |
||||||
|
|
|
|
||||
Backlog of orders 1 |
$ |
136,353 |
|
|
$ |
89,439 |
|
Number of employees |
2,929 |
|
|
2,747 |
|
1. |
Represents customer purchase commitments. While the Company believes these orders are firm, they are generally cancellable by customers without penalty. |
|
|||||||
|
As of |
||||||
|
|
|
|
||||
ASSETS |
|||||||
CURRENT ASSETS |
|
|
|
||||
Cash and cash equivalents |
$ |
392,307 |
|
|
$ |
364,184 |
|
Short-term investments |
248,000 |
|
|
229,000 |
|
||
Accounts and other receivable, net of allowance for doubtful accounts of |
199,793 |
|
|
195,830 |
|
||
Inventories, net |
106,178 |
|
|
89,308 |
|
||
Prepaid expenses and other current assets |
24,149 |
|
|
15,429 |
|
||
TOTAL CURRENT ASSETS |
970,427 |
|
|
893,751 |
|
||
|
|
|
|
||||
Property, plant and equipment, net |
55,647 |
|
|
72,370 |
|
||
Operating right-of-use assets |
22,692 |
|
|
— |
|
||
|
55,946 |
|
|
55,691 |
|
||
Intangible assets, net |
39,757 |
|
|
42,651 |
|
||
Deferred tax assets |
6,975 |
|
|
6,409 |
|
||
Equity investments |
7,427 |
|
|
6,250 |
|
||
Other assets |
2,027 |
|
|
2,494 |
|
||
TOTAL ASSETS |
$ |
1,160,898 |
|
|
$ |
1,079,616 |
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|||||||
CURRENT LIABILITIES |
|
|
|
||||
Short term debt |
$ |
115,617 |
|
|
$ |
60,904 |
|
Accounts payable |
50,530 |
|
|
36,711 |
|
||
Operating lease liabilities |
5,236 |
|
|
— |
|
||
Accrued expenses and other current liabilities |
78,296 |
|
|
64,533 |
|
||
Income taxes payable |
12,358 |
|
|
12,494 |
|
||
TOTAL CURRENT LIABILITIES |
262,037 |
|
|
174,642 |
|
||
|
|
|
|
||||
Financing obligation |
— |
|
|
14,207 |
|
||
Deferred income taxes |
33,690 |
|
|
32,054 |
|
||
Income taxes payable |
74,469 |
|
|
80,290 |
|
||
Operating lease liabilities |
18,550 |
|
|
— |
|
||
Other liabilities |
9,754 |
|
|
9,360 |
|
||
TOTAL LIABILITIES |
398,500 |
|
|
310,553 |
|
||
|
|
|
|
||||
SHAREHOLDERS' EQUITY |
|
|
|
||||
Common stock, no par value |
532,912 |
|
|
533,590 |
|
||
|
(365,095 |
) |
|
(349,212 |
) |
||
Retained earnings |
604,013 |
|
|
594,625 |
|
||
Accumulated other comprehensive loss |
(9,432 |
) |
|
(9,940 |
) |
||
TOTAL SHAREHOLDERS' EQUITY |
$ |
762,398 |
|
|
$ |
769,063 |
|
|
|
|
|
||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
$ |
1,160,898 |
|
|
$ |
1,079,616 |
|
|
|||||||||||||||
|
Three months ended |
|
Six months ended |
||||||||||||
|
|
|
|
|
|
|
|
||||||||
Net cash provided by operating activities |
$ |
14,055 |
|
|
$ |
27,334 |
|
|
$ |
39,083 |
|
|
$ |
83,335 |
|
Net cash (used in)/provided by investing activities |
(131,466 |
) |
|
138,962 |
|
|
(24,979 |
) |
|
73,689 |
|
||||
Net cash provided by/(used in) financing activities |
12,106 |
|
|
(25,176 |
) |
|
14,258 |
|
|
(59,092 |
) |
||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
238 |
|
|
275 |
|
|
(239 |
) |
|
257 |
|
||||
Changes in cash, cash equivalents and restricted cash |
(105,067 |
) |
|
141,395 |
|
|
28,123 |
|
|
98,189 |
|
||||
Cash and cash equivalents, beginning of period |
497,374 |
|
|
277,942 |
|
|
364,184 |
|
|
321,148 |
|
||||
Cash and cash equivalents, end of period |
$ |
392,307 |
|
|
$ |
419,337 |
|
|
$ |
392,307 |
|
|
$ |
419,337 |
|
|
|
|
|
|
|
|
|
||||||||
Short-term investments |
248,000 |
|
|
208,000 |
|
|
248,000 |
|
|
208,000 |
|
||||
Total cash, cash equivalents and short-term investments |
$ |
640,307 |
|
|
$ |
627,337 |
|
|
$ |
640,307 |
|
|
$ |
627,337 |
|
Reconciliation of |
||||||||||||
|
|
Three months ended |
||||||||||
|
|
|
|
|
|
|
||||||
Net revenue |
|
$ |
150,741 |
|
|
$ |
115,908 |
|
|
$ |
144,297 |
|
|
|
11,076 |
|
|
(2,465 |
) |
|
13,414 |
|
|||
|
|
7.3 |
% |
|
(2.1 |
)% |
|
9.3 |
% |
|||
|
|
|
|
|
|
|
||||||
Pre-tax non-GAAP items: |
|
|
|
|
|
|
||||||
Amortization related to intangible assets acquired through business combination- selling, general and administrative |
|
1,820 |
|
|
1,869 |
|
|
1,817 |
|
|||
Restructuring |
|
9 |
|
|
(643 |
) |
|
417 |
|
|||
Non-GAAP income/(loss) from operations |
|
$ |
12,905 |
|
|
$ |
(1,239 |
) |
|
$ |
15,648 |
|
Non-GAAP operating margin |
|
8.6 |
% |
|
(1.1 |
)% |
|
10.8 |
% |
Reconciliation of |
||||||||||||
|
|
Three months ended |
||||||||||
|
|
|
|
|
|
|
||||||
Net revenue |
|
$ |
150,741 |
|
|
$ |
115,908 |
|
|
$ |
144,297 |
|
|
|
11,888 |
|
|
(3,555 |
) |
|
13,477 |
|
|||
|
|
7.9 |
% |
|
(3.1 |
)% |
|
9.3 |
% |
|||
|
|
|
|
|
|
|
||||||
Non-GAAP adjustments: |
|
|
|
|
|
|
||||||
Amortization related to intangible assets acquired through business combination- selling, general and administrative |
|
1,820 |
|
|
1,869 |
|
|
1,817 |
|
|||
Restructuring |
|
9 |
|
|
(643 |
) |
|
417 |
|
|||
Income tax expense- Tax Reform |
|
— |
|
|
2,499 |
|
|
— |
|
|||
Net income tax benefit on non-GAAP items |
|
(27 |
) |
|
28 |
|
|
(51 |
) |
|||
Total non-GAAP adjustments |
|
$ |
1,802 |
|
|
$ |
3,753 |
|
|
$ |
2,183 |
|
Non-GAAP net income |
|
$ |
13,690 |
|
|
$ |
198 |
|
|
$ |
15,660 |
|
Non-GAAP net margin |
|
9.1 |
% |
|
0.2 |
% |
|
10.9 |
% |
|||
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
||||||
Basic |
|
0.19 |
|
|
(0.05 |
) |
|
0.21 |
|
|||
Diluted(a) |
|
0.19 |
|
|
(0.05 |
) |
|
0.21 |
|
|||
|
|
|
|
|
|
|
||||||
Non-GAAP adjustments per share:(b) |
|
|
|
|
|
|
||||||
Basic |
|
0.03 |
|
|
0.05 |
|
|
0.03 |
|
|||
Diluted |
|
0.03 |
|
|
0.05 |
|
|
0.03 |
|
|||
|
|
|
|
|
|
|
||||||
Non-GAAP net income per share: |
|
|
|
|
|
|
||||||
Basic |
|
$ |
0.22 |
|
|
$ |
— |
|
|
$ |
0.24 |
|
Diluted(c) |
|
$ |
0.22 |
|
|
$ |
— |
|
|
$ |
0.24 |
|
(a) |
GAAP diluted net earnings per share reflects any dilutive effect of outstanding restricted stock units and stock options, but that effect is excluded when calculating GAAP diluted net (loss) per share because it would be anti-dilutive. For the three months ended |
|
(b) |
Non-GAAP adjustments per share includes amortization related to intangible assets acquired through business combinations, costs associated with restructuring, income tax expense related to the Tax Cuts and Jobs Act of 2017 as well as tax benefits or expense associated with the foregoing non-GAAP items. |
|
(c) |
Non-GAAP diluted net earnings per share reflects any dilutive effect of outstanding restricted stock units and stock options. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005537/en/
Kulicke & Soffa Industries, Inc.
Investor Relations & Strategic Initiatives
P: +1-215-784-7518
F: +1-215-784-6180